Blue Water Life Science Advisors’s Better Therapeutics, Inc. Common Stock BTTX Stock Holding History

Blue Water Life Science Advisors’s Portfolio BTTX Stock Details BTTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-100,000	Closed	-$465K	–	16
2021 Q4	$465K	Buy	+100,000	New	+$820K	0.14%	13

Other funds holding BTTX

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $143M AUM 102.52% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Blue Water Life Science Advisors's BTTX Position: Q1 2022 in Review

Blue Water Life Science Advisors sold out of Better Therapeutics, Inc. Common Stock (BTTX) in Q1 2022, closing a stake of 100,000 shares — an estimated $465K sold.

Blue Water Life Science Advisors first reported a position in BTTX in Q4 2021 and held it in 1 quarter. The position peaked at $465K in Q4 2021. 14 funds tracked by Wall St. Rank hold BTTX as of Q1 2022.

Blue Water Life Science Advisors reported no remaining Better Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
Blue Water Life Science Advisors sold 100,000 Better Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $465K.
Blue Water Life Science Advisors first reported a position in Better Therapeutics, Inc. Common Stock in Q4 2021 and held it in 1 quarter.
Blue Water Life Science Advisors's Better Therapeutics, Inc. Common Stock position peaked at $465K in Q4 2021.
14 funds tracked by Wall St. Rank held Better Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Blue Water Life Science Advisors's 13F filing for Q1 2022, filed 18 May 2022.